In the mouse model, for example, a PDL1 blocker (atezolizumab) paired with a TGFβ inhibitor resulted in substantial anti-tumor immune cell infiltration (283), whereas the combination of atezolizumab and nab-paclitaxel decreased tumors and extended survival of patients with metastatic triple-negative breast cancer (NCT02425891) (284). This evidence concerns the gene CD274 and triple-negative breast carcinoma.